Your browser doesn't support javascript.
loading
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma, Padmanee; Retz, Margitta; Siefker-Radtke, Arlene; Baron, Ari; Necchi, Andrea; Bedke, Jens; Plimack, Elizabeth R; Vaena, Daniel; Grimm, Marc-Oliver; Bracarda, Sergio; Arranz, José Ángel; Pal, Sumanta; Ohyama, Chikara; Saci, Abdel; Qu, Xiaotao; Lambert, Alexandre; Krishnan, Suba; Azrilevich, Alex; Galsky, Matthew D.
Affiliation
  • Sharma P; Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA; Department of Immunology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA. Electronic address: padsharma@mdanderson.org.
  • Retz M; Department of Urology, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.
  • Siefker-Radtke A; Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Baron A; Department of Medicine, California Pacific Medical Center, San Francisco, CA, USA.
  • Necchi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Bedke J; Department of Urology, University of Tübingen, Tübingen, Germany.
  • Plimack ER; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Vaena D; Division of Hematology, Oncology, and Bone Marrow Transplantation/Department of Medicine and Urology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
  • Grimm MO; Department of Urology, Jena University Hospital, Jena, Germany.
  • Bracarda S; Department of Oncology and Medical Oncology Unit, Ospedale San Donato, Azienda USL Toscana Sud-Est, Istituto Toscano Tumori, Arezzo, Italy.
  • Arranz JÁ; Genitourinary and Gynecologic Section, Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Pal S; Kidney Cancer Program, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Ohyama C; Department of Urology, Hirosaki University, Hirosaki, Aomori, Japan.
  • Saci A; Exploratory Clinical & Translational Research Department, Bristol-Myers Squibb, Princeton, NJ, USA.
  • Qu X; Translational Bioinformatics Department, Bristol-Myers Squibb, Princeton, NJ, USA.
  • Lambert A; Biometrics Department, Bristol-Myers Squibb, Braine-l'Alleud, Belgium.
  • Krishnan S; Global Clinical Research Oncology Department, Bristol-Myers Squibb, Princeton, NJ, USA.
  • Azrilevich A; Global Clinical Research Oncology Department, Bristol-Myers Squibb, Princeton, NJ, USA.
  • Galsky MD; Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY, USA.
Lancet Oncol ; 18(3): 312-322, 2017 03.
Article in En | MEDLINE | ID: mdl-28131785

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Platinum / Carcinoma, Transitional Cell / Urologic Neoplasms / Drug Resistance, Neoplasm / Antibodies, Monoclonal / Neoplasm Recurrence, Local Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Platinum / Carcinoma, Transitional Cell / Urologic Neoplasms / Drug Resistance, Neoplasm / Antibodies, Monoclonal / Neoplasm Recurrence, Local Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Country of publication: United kingdom